Vanrx customers are dispersed across four continents.
A number of our customers have publicly announced their use of Vanrx Workcells. These companies include Adaptive Phage Therapeutics, ADMA Biologics, Amgen, Emergent BioSolutions, FUJIFILM Diosynth Biotechnologies, Roche / Genentech, Moderna, Patheon, Singota Solutions, Wildlife Pharmaceuticals and WuXi Biologics.
Vanrx customers are building filling capacity faster and are prepared for whatever comes down the pipeline. But don’t take our word for it — see for yourself.
Seven months after their purchase order, ADMA Biologics has completed the site acceptance test of an SA25 Aseptic Filling Workcell.
“ADMA Biologics is a manufacturer of life saving, FDA approved plasma derived immune globulin biologic products. Vanrx has helped us move quickly to receive and install our new filling machine, the SA25 Aseptic Filling Workcell during the COVID-19 crisis. We believe the SA25 is an easy-to-use, all-in-one solution for our in-house aseptic filling requirements and will allow ADMA to bring our products to patients faster, improve our margins, as well as substantially increase our end-to-end control over our manufacturing process,” stated Adam Grossman, President & CEO of ADMA Biologics.
Moderna is using a Vanrx SA25 Aseptic Filling Workcell at its Norwood, Massachusetts site for clinical trial supply manufacturing and product development. Their facility won the 2019 ISPE Facility of the Future Award.
WuXi Biologics installed the SA25 Aseptic Filling Workcell at its DP4 drug product operations, reaching its first GMP batch release 15 months after purchasing the machine in 2018. As of April 2020, WuXi Biologics is filling vials, syringes and cartridges for clients at clinical and commercial levels with a quality acceptance rate up to 99.5% of units produced.
DP4 has successfully completed 13 batches of drug product filling and passed six audits with no critical findings. Inspectors included former U.S. FDA officers and EU Qualified Persons. The company has booked 50 future filling projects on to the machine.
Dr. Chris Chen, CEO of WuXi Biologics, commented, “Featuring modularization, robotic automation and a closed system, this state-of-the-art line reflects our leadership in biologics manufacturing innovation. DP4 has demonstrated our diverse aseptic filling capabilities, maintaining high product quality and extensive flexibility to serve the complex biologics filling needs of our clients. WuXi Biologics will continue to invest in cutting-edge technologies to fulfill our mission, enabling global partners to advance product approvals for the benefits of patients worldwide.”
Emergent BioSolutions provides perspective on changing existing commercial products to a new filling line and primary packaging. They moved from conventional filling in an open Grade A cleanroom to the SA25 Aseptic Filling Workcell.Read more
December 17, 2019 - Featured
When looking for a new fill-finish solution for its gene therapy manufacturing operations, CDMO FUJIFILM Diosynth Biotechnologies turned to isolator technology offered by Vanrx Pharmasystems. Thomas Page, Vice President, Engineering and Asset Development, was interviewed by the editor of The Medicine Maker about their experience working with Vanrx.Read More
On November 6, 2018, Dr. Nitin Rathore, Director of Process Development at Amgen, presented 'Implementation of Next-Generation Technologies in Biomanufacturing' at the American Association of Pharmaceutical Scientists (AAPS) Pharma 360 conference in Washington, D.C.Read More
On November 6 at AAPS, Markus Stübchen, Roche’s Global Technical Lead for Large Molecule Drug Product & Clean Utilities, delivered the presentation Novel Approaches for Robotics Use in Sterile Manufacturing. The presentation described how Roche / Genentech will use Vanrx's SA25 as part of a "network" strategy.Read More
How Aseptic Filling Workcells will change your operations.
How filling technologies can automate the filling of advanced therapy medicinal products (ATMPs).
Adaptive Phage Therapeutics (APT) is developing PhageBank, a collection of viruses to kill the most dangerous antibiotic resistant superbugs. Their challenge is to fill multiple viruses every day in building a library of 1,000+ drug products. APT needed a highly agile vial filling system and chose Vanrx’s Microcell Vial Filler to accelerate the process.
Singota Solutions recognized a gap in the market for contract aseptic filling services. They realized that companies developing new drug products and needing to fill batches of 20,000 units or less were underserved by contract manufacturing organizations. They chose Vanrx’s SA25 Aseptic Filling Workcell to provide an agile filling service for vials, syringes and cartridges, with short lead times.Read the case study
In aseptic processing, people are the primary source of contamination. Less human contact during manufacturing means less risk of contamination. To address this issue, Patheon successfully implemented a robotic filling line that operates in a closed isolator environment with no glove ports. This case study takes a look at the technology involved and highlights the implementation team’s experience with installation and qualification.Read the case study
Injectable biologics are growing to focus on small batches of more personalized medicines. Wildlife Pharmaceuticals accepted this change and opted for a small, highly specialized and controlled facility to specifically address their needs. They chose the SA25 Aseptic Filling Workcell. This case study takes a look at Wildlife Pharmaceuticals’ decision process and customer testimonial.Read the case study
From PO to fully qualified in 6 months or less.
From order to installation and validation in 12 months
Flexibly produce either liquid or lyophilized dosages.